Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Lymphomas & Lymphoid Neoplasia

December 20, 2021

A collection of features and news articles published in ASH Clinical News related to lymphomas and lymphoid neoplasia.

Will Pola-R-CHP Be the New Standard Upfront Treatment for Diffuse Large B-Cell Lymphoma?

ASH Clinical News invited Craig Moskowitz, MD, and Joanna M. Rhodes, MD, MSCE, to debate and discuss why a clinician might choose this regimen or not, whether all patients will benefit from upfront pola-R-CHP ...

Tafasitamab, Lenalidomide Plus Firstline R-CHOP Feasible in Diffuse Large B-Cell Lymphoma

For patients with previously untreated DLBCL, treatment with R-CHOP combined with tafasitamab and lenalidomide showed an acceptable safety profile and produced strong response ...

Database Analysis Supports Use of Immunochemotherapy for Primary Central Nervous System Lymphoma

Patients with PCNSL treated with immunochemotherapy had significantly better overall survival compared with patients treated with chemotherapy alone ...

Second-Line Axi-Cel Delivers OS Benefit for R/R LBCL

Second-line treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) significantly improved overall survival (OS) compared with the standard of care in patients ...

DMF Demonstrates Efficacy in R/R CTCL

Dimethyl fumarate (DMF) was effective in the treatment of relapsed and refractory (R/R) cutaneous T-cell lymphoma (CTCL), according to findings from a multicenter phase II study ...

Oral Azacitidine Plus CHOP Shows Efficacy in Treatment-Naïve PTCL

Peripheral T-cell lymphomas (PTCL) are a relatively diverse mix of more than 30 subtypes of aggressive non-Hodgkin lymphomas (NHL) that typically have a poor prognosis when treated with ...

First-Line Subcutaneous Rituximab May Increase PFS in Low Tumor Burden FL

In patients with low tumor burden follicular lymphoma (FL), subcutaneous (SC) rituximab increased progression-free survival (PFS) and complete response (CR) rates when used in induction followed by ....

Combination Therapy for Richter Syndrome Explored

Results from the international phase II MOLTO trial suggest the combination of atezolizumab, venetoclax, and obinutuzumab may provide a more efficacious treatment strategy in patients with ...

Epcoritamab Plus Lenalidomide and Rituximab Yields High Response in R/R FL

Progression of disease within two years (POD24) after initial treatment with chemoimmunotherapy occurs in around 20% of patients with FL. No standard treatment regimen exists for ...

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
Mid-July 2024

Advertisement intended for health care professionals

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals